(Source: Actelion Ltd) UPTRAVI - FDA approved on 21 December 2015 for treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression and reduce the risk of hospitalization for PAH - now available for patients in the US SOUTH SAN FRANCISCO - 04 January 2016 - Actelion (SIX: ATLN) today announced the commercial availability of the oral, selective, IP prostacyclin receptor agonist, UPTRAVI (selexipag) for the treatment of pulmonary arterial hypertension (PAH) in the US. UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness was...
↧